Cargando…
ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment
The US Food and Drug Administration (FDA) developed a draft guidance for drug development in amyotrophic lateral sclerosis (ALS) that was issued in February 2018. The FDA draft guidance considered the recommendations developed by the ALS community that incorporated the views of a large group of clin...
Autores principales: | Andrews, Jinsy A., Bruijn, Lucie I., Shefner, Jeremy M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656654/ https://www.ncbi.nlm.nih.gov/pubmed/31171646 http://dx.doi.org/10.1212/WNL.0000000000007695 |
Ejemplares similares
-
International consensus guidance for management of myasthenia gravis: Executive summary
por: Sanders, Donald B., et al.
Publicado: (2016) -
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
por: Narayanaswami, Pushpa, et al.
Publicado: (2021) -
Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
por: van den Berg, Leonard H., et al.
Publicado: (2019) -
Challenges and opportunities in designing clinical trials for neuromyelitis optica
por: Weinshenker, Brian G., et al.
Publicado: (2015) -
Head injury management guidelines for general practitioners
por: Ganz, Jeremy C
Publicado: (2011)